NASDAQ:XLRNAcceleron Pharma Stock Price, Forecast & News

Acceleron Pharma's stock was trading at $84.39 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, XLRN stock has increased by 18.5% and is now trading at $99.99. View which stocks have been most impacted by Coronavirus.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acceleron Pharma in the last year. There are currently 1 sell rating, 1 hold rating and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Acceleron Pharma.

Acceleron Pharma is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Acceleron Pharma.

Acceleron Pharma Inc (NASDAQ:XLRN) posted its quarterly earnings data on Monday, May, 11th. The biopharmaceutical company reported ($0.95) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.86) by $0.09. The biopharmaceutical company earned $4.30 million during the quarter, compared to the consensus estimate of $5.26 million. Acceleron Pharma had a negative return on equity of 30.14% and a negative net margin of 182.31%. The business's revenue was up 53.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned ($0.74) earnings per share. View Acceleron Pharma's earnings history.

13 equities research analysts have issued twelve-month target prices for Acceleron Pharma's stock. Their forecasts range from $71.00 to $140.00. On average, they expect Acceleron Pharma's share price to reach $117.62 in the next year. This suggests a possible upside of 17.6% from the stock's current price. View analysts' price targets for Acceleron Pharma.

News headlines about XLRN stock have been trending neutral this week, InfoTrie Sentiment reports. The research group scores the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Acceleron Pharma earned a media sentiment score of 0.2 on InfoTrie's scale. They also assigned headlines about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news about Acceleron Pharma.

Some companies that are related to Acceleron Pharma include NOVOZYMES A/S/S (NVZMY), BioNTech (BNTX), Neurocrine Biosciences (NBIX), argenx (ARGX), BIO-TECHNE (TECH), Qiagen (QGEN), Repligen (RGEN), Adaptive Biotechnologies (ADPT), Crispr Therapeutics (CRSP), Novavax (NVAX), Allogene Therapeutics (ALLO), Spark Therapeutics (ONCE), China Biologic Products (CBPO), Momenta Pharmaceuticals (MNTA) and Iovance Biotherapeutics (IOVA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Acceleron Pharma investors own include Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Incyte (INCY), Intel (INTC), NVIDIA (NVDA), Bausch Health Companies (BHC), Cisco Systems (CSCO), LogicBio Therapeutics (LOGC), Corcept Therapeutics (CORT) and FibroGen (FGEN).

Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN."

Acceleron Pharma's stock is owned by a number of institutional and retail investors. Top institutional investors include Polianta Ltd (0.02%), Envestnet Asset Management Inc. (0.01%) and Nelson Van Denburg & Campbell Wealth Management Group LLC (0.01%). Company insiders that own Acceleron Pharma stock include Adam M Veness, Corp /De/ Celgene, Habib J Dable, Jean George, John D Quisel, Joseph S Zakrzewski, Kevin F Mclaughlin, Ravindra Kumar and Sujay Kango. View institutional ownership trends for Acceleron Pharma.

XLRN stock was sold by a variety of institutional investors in the last quarter, including Envestnet Asset Management Inc.. Company insiders that have sold Acceleron Pharma company stock in the last year include Adam M Veness, Habib J Dable, John D Quisel, Kevin F Mclaughlin, Ravindra Kumar, and Sujay Kango. View insider buying and selling activity for Acceleron Pharma.

XLRN stock was purchased by a variety of institutional investors in the last quarter, including Polianta Ltd, and Nelson Van Denburg & Campbell Wealth Management Group LLC. Company insiders that have bought Acceleron Pharma stock in the last two years include Corp /De/ Celgene, and Joseph S Zakrzewski. View insider buying and selling activity for Acceleron Pharma.

Shares of XLRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of XLRN stock can currently be purchased for approximately $99.99.

Acceleron Pharma has a market capitalization of $5.38 billion and generates $73.99 million in revenue each year. The biopharmaceutical company earns $-124,860,000.00 in net income (profit) each year or ($2.38) on an earnings per share basis. Acceleron Pharma employs 173 workers across the globe.

The official website for Acceleron Pharma is www.acceleronpharma.com.

Acceleron Pharma's mailing address is 128 SYDNEY STREET, CAMBRIDGE MA, 02139. The biopharmaceutical company can be reached via phone at 617-649-9200 or via email at [email protected]